2022 Original Papers / 2022 原著論文
- Yamamoto, H.; Nagumo, Y.; Ishikawa, Y.; Irukayama-Tomobe, Y.; Namekawa, Y.; Nemoto, T.; Tanaka, H.; Takahashi, G.; Tokuda, A.; Saitoh, T.; Nagase, H.; Funato, H.; Yanagisawa, M.
“OX2R-selective orexin agonism is sufficient to amelioratecataplexy and sleep/wake fragmentation without inducing drug-seeking behavior in mouse model of narcolepsy”
PLOS ONE 2022, 17, e0271901. (web) - Kitano, M.; Saitoh, T.; Nishiyama, S.; Einaga, Y.; Yamamoto, T.
“Electro-conversion of cumene into acetophenone using boron-doped diamond electrodes”
Beilstein J. Org. Chem. 2022, 18, 1154-1158. (web) - Saitoh, T.; Amezawa, M.; Horiuchi, J.; Nagumo, Y.; Yamamoto, N.; Kutsumura, N.; Ohshita, R.; Tokuda, A.; Irukayama-Tomobe, Y.; Ogawa, Y.; Ishikawa, Y.; Hasegawa, E.; Sakurai, T.; Uchida, Y.; Sato, T.; Gouda, H.; Tanimura, R.; Yanagisawa, M.; Nagase, H.
“Discovery of novel orexin receptor antagonists using a 1,3,5-trioxazatriquinane bearing multiple effective residues (TriMER) library“
Eur. J. Med. Chem. 2022, 240, 114505. (web) - Kawaminami, A.; Yamada, D.; Yanagisawa, S.; Shirakata, M.; Iio, K.; Nagase, H.; Saitoh, A.
“Selective δ-Opioid Receptor Agonist, KNT-127, Facilitates Contextual Fear Extinction via Infralimbic Cortex and Amygdala in Mice”
Front. Behav. Neurosci. 2022, 16, 808232. (web) - Yamauchi, T.; Yoshioka, T.; Yamada, D.; Hamano, T.; Ohashi, M.; Matsumoto, M.; Iio, K.; Ikeda, M.; Kamei, M.; Otsuki, T.; Sato, Y.; Nii, K.; Suzuki, M.; Ichikawa, H.; Nagase, H.; Iriyama, S.; Yoshizawa, K.; Nishino, S.; Miyazaki, S.; Saitoh, A.
“Cold-Restraint Stress-Induced Ultrasonic Vocalization as a Novel Tool to Measure Anxiety in Mice”
Biol. Pharm. Bull. 2022, 45, 268-275. (web) - Iio, K.; Saitoh, T.; Ohshita, R.; Hino, T.; Amezawa, M.; Takayama, Y.; Nagumo, Y.; Yamamoto, N.; Kutsumura, N.; Irukayama-Tomobe, Y.; Ishikawa, Y.; Tanimura, R.; Yanagisawa, M.; Nagase, H.
“Discovery of orexin 2 receptor selective and dual orexin receptor agonists based on the tetralin structure: Switching of receptor selectivity by chirality on the tetralin ring”
Bioorg. Med. Chem. Lett. 2022, 60, 128555. (web) - Katoh, K.; Kutsumura, N.; Yamamoto, N.; Nagumo, Y.; Saitoh, T.; Ishikawa, Y.; Irukayama-Tomobe, Y.; Tanimura, R.; Yanagisawa, M.; Nagase, H.
“Essential structure of orexin 1 receptor antagonist YNT-707: Conversion of the 16-cyclopropylmethyl group to the 16-sulfonamide group in D-nor-nalfurafine derivatives”
Bioorg. Med. Chem. Lett. 2022, 59, 128550. (web) - Hino, T.; Saitoh, T.; Nagumo, Y.; Yamamoto, N.; Kutsumura, N.; Irukayama-Tomobe, Y.; Ishikawa, Y.; Tanimura, R.; Yanagisawa, M.; Nagase, H.
“Design and synhtesis of novel orexin 2 receptor agonists based on naphthalene skeleton”
Bioorg. Med. Chem. Lett. 2022, 59, 128530. (web) - Katoh, K.; Yamamoto, N.; Ishikawa, Y.; Irukayama-Tomobe, Y.; Tanimura, R.; Saitoh, T.; Nagumo, Y.; Kutsumura, N.; Yanagisawa, M.; Nagase, H.
“Effect of removal of the 14-hydroxy group on the affinity of the 4,5-epoxymorphinan derivatives for orexin and opioid receptors”
Bioorg. Med. Chem. Lett. 2022, 59, 128527. (web) - Iio, K.; Kutsumura, N.; Nagumo, Y.; Saitoh, T.; Tokuda, A.; Hashimoto, K.; Yamamoto, N.; Kise, R.; Inoue, A.; Mizoguchi, H.; Nagase, H.
“Synthesis of unnatural morphinan compounds to induce itch-like behaviors in mice: Towards the development of MRGPRX2 selective ligands”
Bioorg. Med. Chem. Lett. 2022, 56, 128485. (web)
